None listed
Conditions
Interventions
Intervention1: Cap. Acteoside 25 mg: Will receive Cap. Acteoside 25 mg TDS for three months.
Control Intervention1: Tab Silymarin 140mg: Tab Silymarin 140 mg twice a day for three months
Sponsors
Government Medical College, Jammu
Indian Institute of Integrative Medicine, Jammu
Eligibility
Inclusion criteria
Inclusion criteria: Acute Hepatitis Patients of different etiologies in the age group of 20-65 years and would be required to abstain from any alternative medication or vitamin supplements during the study.
Exclusion criteria
Exclusion criteria: 1. Patients having any other concomitant disease 2.Patients receiving any other medication affecting hepatic function 3. Patients having received any hepatoprotective agent in the recent past or currently on any hepatoprotective agent 4.Patients with history of smoking, alcohol or any other substance abuse. 5. Pregnancy and lactation. 6. Has participated in any investigational study 4 weeks prior to the enrollment in this study. 7. Known history of hypersensitivity reactions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The patients will be evaluated for various parameters like general well being, hepatic size change, improvement in liver function tests serological markers and antioxidant parameters compared to baseline using appropriate statistical testTimepoint: 0 day,2,4,8 and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Not ApplicableTimepoint: Not Applicable | — |
Countries
India
Contacts
Public ContactDr. J. P. Singh
Prof & Head, Post Graduate Department of Pharmacology & Therapeutics
Outcome results
None listed